TITLE

Breast plasmacytoma

AUTHOR(S)
Surov, Alexey; Holzhausen, Hans-Jürgen; Ruschke, Katrin; Arnold, Dirk; Spielmann, Rolf-Peter
PUB. DATE
May 2010
SOURCE
Acta Radiologica;May2010, Vol. 51 Issue 5, p498
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Breast plasmacytoma (BP) is extremely rare. The published data on this manifestation include predominantly case reports and do not provide any statistical information. Purpose: To identify clinical signs and radiological features of BP. Material and Methods: Five patients with BP were retrospectively identified in the pathological and radiological databases of the years 1997–2009 at our institution. Additionally, 48 patients were collected from the literature in the period from 1988 to date. Therefore, our study involves 53 patients. Results: The prevalence of BP in our institution was 1.5% of all identified cases with plasmacytoma and 0.2% of the cases with breast cancer. In 8 of 53 patients (15%), primary BP was diagnosed, and in 45 patients (85%) involvement of the breast was a secondary event of the multiple myeloma (MM). Clinically, 83% of the patients presented with breast lumps. BP was diagnosed incidentally in 9%. In 8% of the cases clinical signs were not reported. On mammography, intramammary round or oval masses were most commonly found (89%). They were solitary in 66% of the cases and multiple in 34%. Median size was 21 mm, ranging from 8 to 90 mm. In 9% of the identified cases BP manifested as diffuse infiltration of the breast. In 2% no abnormalities were identified on mammography. On ultrasound, identified lesions were homogeneously echo-poor or hypoechoic, less frequently mixed hypo- to hyperechoic. Treatment of BP is the same as for other localizations of plasmacytoma and is based on chemotherapy and/or radiotherapy. Primary BP had a better prognosis than breast involvement as a secondary event in MM. Conclusion: In conclusion, BP does not have specific radiological or clinical features and can be misdiagnosed as primary breast carcinoma or even as a benign process. However, BP should be considered in the differential diagnosis of breast disorders, especially in patients with MM.
ACCESSION #
50615509

 

Related Articles

  • Mayo Clinic Researchers Announce Promising Next Generation Treatments for Multiple Myeloma.  // Ascribe Newswire: Medicine;12/6/2004, p10 

    The article discusses the treatments for Multiple Myeloma. The combination of two pills� thalidomide and dexamethasone� may be an effective alternative to the intravenous chemotherapy commonly prescribed to patients with multiple myeloma, according to a large collaborative study...

  • Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. Renshaw, Christine; Ketley, Nicolas; Møller, Henrik; Davies, Elizabeth A. // BMC Cancer;2010, Vol. 10, p74 

    Background: Multiple myeloma is an uncommon cancer with a poor prognosis. Its incidence is expected to increase due to ageing populations and better diagnosis, and new treatments have been developed to improve survival. Our objective was to investigate trends in the epidemiology and survival of...

  • Enhancing area surrounding breast carcinoma on MR mammography: comparison with pathological examination. Van Goethem, M.; Schelfout, K.; Kersschot, E.; Colpaert, C.; Verslegers, I.; Biltjes, I.; Tjalma, W. A.; Weyler, J.; De Schepper, A. // European Radiology;Aug2004, Vol. 14 Issue 8, p1363 

    The enhancing area surrounding breast carcinoma on MR mammography is correlated with findings from pathological examination. We studied 194 patients with breast cancer who underwent preoperative MR mammography. Of all malignant lesions presenting with an enhancing surrounding area on MR...

  • Mammograms: Worth it? Harrar, Sarí N. // Prevention;Mar2006, Vol. 58 Issue 3, p45 

    The article reports on a study that has found that mammograms are as effective at saving the lives of breast cancer patients as new treatments are. Researchers in the United States and the Netherlands examined statistics on detection, treatment and survival rates to determine what had caused the...

  • Breast cancer screening less accurate in survivors.  // Tennessee Tribune;3/3/2011, Vol. 22 Issue 9, p3B 

    The article reports on the findings of the government-funded study which reveals that screening mammography is less accurate at spotting breast cancer among survivors.

  • Imaging Findings of Plasmacytoma of Both Breasts as a Preceding Manifestation of Multiple Myeloma. Park, Young Mi // Case Reports in Medicine;1/27/2016, p1 

    Breast plasmacytoma is an extremely rare tumor. It can occur as a primary isolated tumor or as an extramedullary manifestation in multiple myeloma. This report describes the unusual case of a primary extramedullary plasmacytoma that progressed to multiple myeloma within 15 months in a...

  • Melphalan.  // Reactions Weekly;3/27/2010, Issue 1294, p26 

    The article describes the case of a woman with light chain deposition disease who experienced a deterioration of renal function, while receiving melphalan for multiple myeloma.

  • Bortezomib/itraconazole/voriconazole interaction.  // Reactions Weekly;3/16/2013, Issue 1444, p12 

    The article presents the case of two patients with multiple myeloma (MM), who developed paralytic ileus and peripheral neuropathy while receiving bortezomib along with itraconazole or voriconazole.

  • Respiratory Distress in a Patient With Multiple Myeloma. Bush, Nancy Jo; Griffin-Sobel, Joyce P.; Frausto, Lilia // Oncology Nursing Forum;Aug2002, Vol. 29 Issue 7, p1041 

    Presents the case of a patient with refractory multiple myeloma. Assessment of patients with multiple myeloma; Difference of the diagnosis of the disease from that of plasmacytoma; Care for patients with multiple myeloma.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics